

Clinical Observation on Xiaoluo Mixture I Combined With Chemical Medicine for 43 Cases of Cervical Lymphadenopathy

ZHOU Min¹, LI Fujian², HUANG Liqin¹, NI Kefeng¹

(1. Hangzhou TCM Hospital, Zhejiang Province 310007; 2. Hangzhou Red Cross Hospital)

ABSTRACT **Objective** To observe the therapeutic effect of Xiaoluo Mixture I for cervical lymphadenopathy (CL). **Methods** Sixty cases of CL were randomized into the treatment group and control group, with 30 in each. The control group was given routine western medicine. The treatment group was added with Xiaoluo Mixture I one dose daily. The treatment lasted for 4 months. The efficacy was observed. The TCM symptom scores were evaluated before and after treatment. The levels of interferon- γ (IFN- γ) and tumor necrosis factor- α (TNF- α) were detected. The adverse reactions were compared. **Results** The total effective rate of the treatment group and control group was 86. 4% and 66. 7% respectively, with a significant difference between groups ($P < 0.05$). The symptoms such as depression, poor appetite, fever and fatigue were significantly relieved in the treatment group after treatment ($P < 0.05$). Comparing with the control group, poor appetite and fatigue were significantly relieved in the treatment group after treatment ($P < 0.05$). The IFN- γ level was significantly increased but the TNF- α level was significantly decreased in the treatment group after treatment ($P < 0.05$). There was no significant difference between groups in the TNF- α level after treatment ($P > 0.05$). **Conclusion** Xiaoluo Mixture I could improve the immune capacity and symptoms in the treatment of CL.

Keywords cervical lymphadenopathy; Xiaoluo Mixture I; interferon- γ ; tumor necrosis factor- α

(收稿日期: 2014-03-04; 修回日期: 2014-06-26)

[编辑: 侯建春]

2014 年国家中医药继续教育项目 中药上市后大品种二次研发高层培训班通知

由世界中医药学会联合会国际合作部、《世界中医药》杂志社联合主办的国家中医药继续教育项目“中药上市后大品种二次研发高层培训班”拟于 2014 年 10 月 24 日至 27 日在北京举办。由北京华盛国际医药信息交流中心、北京漫青国际医药科技有限公司承办。中国中医科学院中药所药物安全性评价中心主任、博士生导师、世界中联中药新型给药系统专业委员会会长、药品管理与中药知识产权保护委员会主任委员叶祖光首席研究员, 中国中医科学院临床医院研究所副所长谢雁鸣研究员、中国中医科学院西苑医院原院长翁维良首席研究员以及上海中医药大学张磊教授(原国家药审中心中医临床部部长)等专家主讲。

1. 培训内容: (1) 中成药大品种上市后再评价; (2) 循证医学在中药临床再评价中的应用; (3) 中药注射剂的风险评估与管理; (4) 基于真实世界的临床研究; (5) 中药 IV 期临床研究与再评价; (6) 基于临床的中药新药研发; (7) 中药上市后合理用药的研究与评价; (8) 中药上市后安全性再评价的研究; (9) 中成药进入医保社保相关政策解读; (10) 中药新药临床研究进展等。

2. 培训对象: 各医药企事业单位相关人员及从事科研、市场、媒体筹划、产品研发、公共事务部、学术推广等人员和各大专院校医院科研管理及研究人员等。

3. 培训时间与学费: (1) 学期 4 天(报到 1 天, 授课 3 天), 每位学员学费 2960 元/人, 海外学员 3980 元/人(含午餐、场地费、讲议费、专家课时费、证书费、纪念品等)。报名时交本人身份证复印件, 2 寸免冠照片 2 张。(2) 学员须提前报名, 报名费 200 元/人(在学费中扣减), 报满 50 人即开班, 提前 2 个月报名者学费优惠 10%。

4. 学满课时待遇: 学员学满课时颁发国家中英文对照结业证书, 并授予 I 类学分 12 学分证书。参加学习班的学员文章投稿至《世界中医药》达到登刊标准者优先发表。

5. 联系地址: 北京市朝阳区小营路 19 号财富嘉园 A 座 301 室, 世界中医药学会联合会国际合作部。邮编: 100101。联系人: 王炳岐(13901318403), 邓爱英(13051608026), 邮箱: 13901318403@139.com, 电话/传真: (010) 58239066, 叶恒(13501288390), 邮箱: hy0388@163.com。培训地址暂定于中国中医科学院。